Can storytelling and support groups break the stigma around cancer in rwanda?

NCT ID NCT07663006

Not yet recruiting Knowledge-focused Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how common stigma is for breast and cervical cancer patients, caregivers, and community health workers in Rwanda. It also tests a program called RISE that includes resilience training, support groups, and videos of cancer survivors to see if it can reduce stigma. The goal is to find ways to make people feel more comfortable talking about cancer and seeking help.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RISE Intervention (resilience training, support groups, survivor videos) and CHW Educational Intervention (survivor videos, educational materials)
What this could lead to: If successful, this could provide a proven way to reduce cancer stigma in Rwanda, improving support for patients and encouraging earlier diagnosis.
What could go wrong: This is a pilot study, so the intervention may not reduce stigma as hoped. Results may also not apply to other regions or cultures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER CERVICAL CANCER

Contacts and locations

Locations

Butaro Level 2 Teaching Hospital (BL2TH), Ministry of Health

Butaro, Rwanda
University of Global Health Equity (UGHE)

Butaro, Rwanda

More trials for these conditions

Other studies related to the condition(s) this trial covers.